Friday, July 20, 2018

Merck To Steeply Cut Price of Hepatitis C Drug Zepatier

Merck To Steeply Cut Price of Hepatitis C Drug Zepatier
July 20, 2018
The company announced that it plans to reduce other drugs in its portfolio as well. Merck will drop the price of its Hepatitis C drug Zepatier by 60%, the company announced yesterday. In addition, it plans to cut the price of “several other” drugs by 10%. In doing so, Merck went further than two competitors—Pfizer and Novartis—who said that they would not increase drug prices for the rest of 2018.
Read more:

Merck Is Lowering Drug Prices. There’s a Catch
July 19, 2018
The drugmaker Merck said Thursday that it would lower prices on several drugs by 10 percent or more, but its rollback affects minor products and would not lower the cost of its top-selling, expensive cancer and diabetes products.
Read more:

Of Interest
Roche Hiked Cancer-Drug Prices Before Pledge to Keep Them Flat
‎July‎ ‎20‎, ‎2018
For example, Fazeli said, Merck's hepatitis C treatment Zepatier was already facing competition from a cheaper, shorter-course treatment from AbbVie Inc. Merck said on Thursday it would cut Zepatier’s price by 60 percent as part of a commitment to responsible pricing. But the company probably would already have had to apply a hefty discount to the list price, Fazeli said.
Louisiana's New Approach To Treating Hepatitis C
Louisiana is working with Gilead Sciences and other companies on a deal that would change how the state pays for expensive hepatitis C drugs, with the goal of eliminating the disease in that state.
Despite highly effective and well-tolerated regimens for treating hepatitis C virus (HCV), patients face barriers in accessing treatment. In addition to suboptimal HCV screening programs and lack of effective linkage-to-care, other barriers include strict requirements from some payers to cover treatment. This study reports insurance status and Hispanic ethnicity as predictors of not receiving treatment. These barriers occur despite the fact that HCV is the most common indication for liver transplantation and cause of hepatocellular carcinoma in the U.S. Therefore, it is critical that policymakers bring all the stakeholders together and develop a national policy to eradicate HCV infection from the U.S.

July 9, 2018
The controversy over expensive new drugs for hepatitis C
Link to research and news articles addressing the high cost of hepatitis C drugs; insurance restrictions - private insurers/Medicaid - and availability of generic versions.

No comments:

Post a Comment